Abstract National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) is an enhanced prognostic tool and it identified some specific extranodal sites as a poor prognostic factor. We were interested in this issue and retrospectively analyzed 148 Taiwanese patients with newly diagnosed diffuse large B-cell lymphoma under rituximab (R)-CHOP-like regimens from January 2001 to December 2010 at the Tri-Service General Hospital. In the univarate analysis, ≥ 2 extranodal involved sites had no significant prognostic relevance (p=0.108) and extranodal involvement of lung/pleura, liver, lower urinary tract or bone marrow was a statistically significant poor prognostic factor (p<0.001). In the multivariate analysis, some specific extranodal sites had stronger predictive value for poor prognosis [relative risk 3.654, 95% confidence interval 1.514-8.815, p=0.004] than that of numbers of extranodal involvement. This finding suggested that the specific extranodal involved sites have a great prognostic value in the R era.